Transgene
Developing viral immunotherapies like vaccines and oncolytic viruses to treat solid tumors.
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapeutics for the treatment of cancer. The company specializes in creating therapeutic vaccines and oncolytic viruses designed to harness the patient's immune system to fight tumors. Its pipeline is built upon proprietary viral vector technologies, including the invir.IO® platform, which generates innovative multifunctional oncolytic viruses capable of modulating the tumor microenvironment. Transgene's product candidates are being evaluated in clinical trials for various solid tumors, including head and neck cancers and metastatic colorectal cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-04 17:50 |
Business and Financial Review
Transgene Provides Business and Financial Update for Q3 2025
|
English | 453.1 KB | ||
| 2025-11-04 17:50 |
Earnings Release
Transgene fait le point sur ses activités et sa situation financière au troisiè…
|
French | 345.9 KB | ||
| 2025-11-04 17:45 |
Regulatory News Service
New Phase I Immunological Data Presented at SITC 2025 Support TG4050’s Potentia…
|
English | 451.7 KB | ||
| 2025-11-04 17:45 |
Regulatory News Service
Les nouvelles données d’immunologie de la Phase I de TG4050 présentées au SITC …
|
French | 447.9 KB | ||
| 2025-10-03 17:45 |
Regulatory News Service
Transgene présente de nouvelles données d’immunologie de la Phase I de TG4050, …
|
French | 405.9 KB | ||
| 2025-10-03 17:45 |
Regulatory News Service
Transgene to Present New Immunological Data from Phase I Trial of Individualize…
|
English | 396.4 KB | ||
| 2025-09-16 17:45 |
Earnings Release
Données positives de la Phase I randomisée de TG4050, vaccin thérapeutique indi…
|
French | 684.0 KB | ||
| 2025-09-16 17:45 |
Report Publication Announcement
Mise à disposition du Rapport Financier Semestriel au 30 juin 2025
|
French | 209.1 KB | ||
| 2025-09-16 17:45 |
Earnings Release
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Deliver…
|
English | 558.3 KB | ||
| 2025-09-16 17:45 |
Report Publication Announcement
Availability of Transgene’s Half-Year Financial Report as of June 30, 2025
|
English | 221.5 KB | ||
| 2025-07-09 17:45 |
Board/Management Information
Transgene nomme une experte de l’industrie pharmaceutique, Emmanuelle Quilès, e…
|
French | 387.4 KB | ||
| 2025-07-09 17:45 |
Board/Management Information
Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Di…
|
English | 255.1 KB | ||
| 2025-06-19 08:00 |
Legal Proceedings Report
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial …
|
English | 310.5 KB | ||
| 2025-06-19 08:00 |
Legal Proceedings Report
Transgene finalise la sélection initiale de patients pour la partie Phase II de…
|
French | 304.7 KB | ||
| 2025-06-13 08:30 |
Report Publication Announcement
Transgene participera à plusieurs rencontres avec des acteurs clés de la biotec…
|
French | 304.7 KB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Transgene
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
Peer Companies
